N (%) |  | Total (N = 2553) | Before VTE (N = 208) | Before PE (N = 93) | Before bleeding (N = 341) |
---|---|---|---|---|---|
Lung cancer surgery | No | 2052 (80.4) | 181 (87.0) | 83 (89.3) | 280 (82.1) |
 | Yes | 501 (19.6) | 27 (13.0*) | 10 (10.8) | 61 (17.9) |
Other surgery | No | 1970 (77.2) | 156 (75.0) | 73 (78.5) | 279 (81.8) |
 | Yes | 583 (22.8) | 52 (25.0) | 20 (21.5) | 62 (18.2) |
Chemotherapy | No | 1201 (47.0) | 72 (34.6) | 35 (37.6) | 217 (63.6) |
 | Yes | 1352 (53.0) | 136 (65.4) | 58 (62.4) | 124 (36.4) |
+ Bevacizumab | No | 1244 (92.0) | 125 (91.9) | 55 (91.4) | 117 (94.4) |
 | Yes | 108 (8.0) | 11 (8.1) | 3 (8.6) | 7 (5.7) |
Oral lung cancer targeted therapy | No | 2340 (91.7) | 201 (96.6) | 87 (93.6) | 333 (97.7) |
 | Yes | 213 (8.3) | 7 (3.4) | 6 (6.5) | 8 (2.4) |
Radiotherapy | No | 1711 (67.0) | 155 (74.5) | 68 (73.1) | 274 (80.4) |
 | Yes | 842 (33.0) | 53 (25.5) | 25 (26.9) | 67 (19.7) |
Blood transfusion | No | 2253 (88.3) | 190 (91.4) | 86 (92.5) | 290 (85.0) |
 | Yes | 300 (11.8) | 18 (8.7) | 7 (7.5) | 51 (15.0) |
Non-surgical hospitalisation†| No | 1065 (41.7) | 122 (58.7) | 52 (55.9) |  |
 | Yes | 1488 (58.3) | 86 (41.4) | 41 (44.1) |  |